The latest results from an international Phase III clinical study, show that pomalidomide with low-dose dexamethasone improves the length of remission and extends overall survival in relapsed and refractory myeloma patients.
Pomalidomide, an immunomodulatory drug (IMiD) similar to Revlimid® and derived from thalidomide, is being developed by the pharmaceutical company Celgene as a potential treatment in myeloma. Continue reading
MPE has welcomed the news today that the European Commission has approved a marketing licence for Velcade to be used as a subcutaneous (under the skin) injection for myeloma patients.
Velcade was the first in a class of anti-cancer drugs called proteasome inhibitors to be used in myeloma. It was first licensed in Europe in an IV formulation and since then Velcade has had a significant impact on the treatment of myeloma. Continue reading